EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.